# A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC

> **NCT05378867** · PHASE3 · UNKNOWN · sponsor: **Zhejiang Teruisi Pharmaceutical Inc.** · enrollment: 126 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (CRC)

## Interventions

- **BIOLOGICAL:** TRS003
- **BIOLOGICAL:** China-approved Bevacizumab
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT05378867
- **Lead sponsor:** Zhejiang Teruisi Pharmaceutical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05378867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05378867, "A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05378867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*